Industry & Intelligence
Consolidated sales of €14.3 million. Operating cash flow briefly positive. A portfolio spanning medical cannabis import, industrial hemp, CBD brands, and a telemedicine platform. On paper, by early 2024, SynBiotic SE looked like the integrated European cannabis company its earliest backers had wagered on. Months later, it filed for insolvency.
The German cannabis group — once among the largest listed cannabis businesses in Europe, with a notional market capitalisation of around €85 million at pre-crisis analyst valuations — announced this week that it would file for insolvency proceedings. The Frankfurt and Xetra stock exchanges have suspended its shares. The filing follows a year in which six of its subsidiaries had already collapsed, been wound down, or disposed of, and in which its auditor declined to issue an opinion on the group's accounts.
How a Roll-Up Became a Warning
SynBiotic's story is worth tracing carefully, because it is not primarily a story of a bad company. It is a story of a structural bet that went wrong at precisely the wrong moment.
The group was built through aggressive acquisition. Its most significant early move, according to reporting by Business of Cannabis, was an €11.2 million merger that brought Hanf Farm, Hempro International, Hemp Factory, and MH Medical Hemp under one roof. The seller was Daniel Kruse, a past president of the European Industrial Hemp Association (EIHA) and a prominent figure in European hemp commerce. Kruse joined the SynBiotic structure through the deal and eventually became CEO in August 2023, replacing founder Lars Müller.
The investor register read like a who's-who of European alternative asset ambition. Christian Angermayer's Apeiron Investment Group — whose health and biotech portfolio also includes Compass Pathways and ATAI Life Sciences — backed SynBiotic from September 2021. Bruce Linton, the founder of Canopy Growth who had taken that Canadian company to a NYSE listing and secured Constellation Brands' multi-billion-dollar investment, joined as an investor in November 2022. German media entrepreneur Frank Otto of the Otto family invested €3 million through a share package and joined the Verwaltungsrat, the company's supervisory board, in 2023.
Revenue guidance for full-year 2021 had been raised to €15 million, up from €5.4 million in 2020. The group was adding platforms: in mid-2024 it took a 50.2% stake in Greensby UG, a European platform connecting patients, pharmacies, and telemedicine providers, and lined up a full acquisition of Croatian CBD isolate manufacturer Ilesol Pharmaceuticals.
The CanG Problem
When Germany's Cannabis Act (CanG) came into force in April 2024, it was supposed to be the moment SynBiotic capitalised on years of positioning. Germany's medical cannabis market had already been expanding sharply, with patient numbers, prescriptions, and import tonnage rising. CanG was expected to accelerate that further.
It did. Just not for SynBiotic.
The group's medical spine ran through WEECO Pharma, its import and wholesale platform. As CanG opened up the German market, the companies that captured the growth were those running telemedicine clinics and online pharmacies — the businesses closest to the consumer. SynBiotic sold wholesale into that chain. It absorbed the downward price pressure that intensified as import volumes rose, without capturing any of the margin that flowed to consumer-facing operators above it.
Consolidated sales jumped 270.5% from €3.9 million in 2023 to €14.3 million in 2024, and operating cash flow briefly turned positive at €0.7 million. But those figures masked what was happening at the SynBiotic SE holding company level, where cash was haemorrhaging. Shareholders at the group's last annual meeting refused to approve the creation of new authorised capital, blocking the flexible fundraising the management had argued was essential to the group's continued existence. The financing that management had been counting on never arrived.
What This Means for European Cannabis Capital
SynBiotic's insolvency does not mean the European cannabis market is failing. Germany's patient numbers are rising. The regulatory direction across the continent is, slowly, towards liberalisation. Malta's own decade of cannabis reform is part of a broader European shift that continues regardless of individual company outcomes.
What SynBiotic does illustrate, with considerable clarity, is that roll-up strategies in immature markets carry layered risks that consolidated revenue figures do not reveal. A holding company aggregating subsidiaries in a capital-light model can look healthy at the portfolio level while quietly running out of runway at the top. When the market finally moves — as Germany's did after CanG — the benefits flow to operators with direct consumer relationships, not to wholesale intermediaries sitting between them.
For European cannabis investors, lenders, and the entrepreneurs building the next generation of regional platforms, SynBiotic's trajectory is now required reading. The group had credible investors, experienced operators, genuine revenue growth, and a market tailwind. It still ran out of road.
The insight that sits uncomfortably beneath the headline numbers: in a rapidly commoditising wholesale market, scale without margin control is not a moat. It is exposure.
Whether the underlying assets — the hemp brands, the patient platform, the Croatian isolate operation — survive in new hands remains to be seen. But the question worth holding onto is simpler: when Germany's cannabis market was finally, genuinely growing, why did the company built to ride that wave end up being swept under it?
Sources:
Business of Cannabis — German Cannabis Pioneer SynBiotic SE Files For Insolvency
https://businessofcannabis.com/german-cannabis-pioneer-synbiotic-se-files-for-insolvency/
Featured image: Photo by Alesia Kozik on Pexels
Members Discussion